AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31755939 — intervention group
Group type: EXPERIMENTAL
Intervention: Eosinophil percentage of white cells
Number of subjects: 375000
Study 31755939 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombin‐activatable fibrinolysis inhibitor activation peptide antigen
Number of subjects: 375000
Study 31755939 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically lower levels of factor XI
Number of subjects: 375000
Study 31755939 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor VIII and γ' fibrinogen
Number of subjects: 375000
Study 31018869 — intervention group
Group type: EXPERIMENTAL
Intervention: Footwear intervention (podiatric care and gout education plus a commercially available athletic shoe)
Number of subjects: 94
Study 31018869 — intervention group
Group type: COMPARATOR
Intervention: Control group (podiatric care and gout education)
Number of subjects: 94
Study 29726748 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation
Number of subjects: 112
Study 29726748 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (Control)
Number of subjects: 112
Study 26844011 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and exercise
Number of subjects: 181
Study 24558998 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein
Number of subjects: 10
Study 24558998 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein
Number of subjects: 10
Study 24558998 — intervention group
Group type: COMPARATOR
Intervention: Control drink
Number of subjects: 10
Study 21793899 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% N-acetylcarnosine lubricant eye drops
Number of subjects: 161000000
Study 21793899 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic administration of carcinine
Number of subjects: 161000000
Study 21793899 — intervention group
Group type: EXPERIMENTAL
Intervention: Parabulbar, subconjunctival, and intravitreal injection of carcinine
Number of subjects: 161000000
Study 20642550 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg once daily)
Number of subjects: 11
Study 20642550 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg once daily) and Itraconazole (200 mg once daily)
Number of subjects: 11
Study 20642550 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 17451383 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% minoxidil solution twice daily for 12 months
Number of subjects: 103
Study 17451383 — intervention group
Group type: COMPARATOR
Intervention: 0.025% alfatradiol solution once daily for 6 months, then 2% minoxidil for months 7-12
Number of subjects: 103
Study 15920714 — intervention group
Group type: EXPERIMENTAL
Intervention: Health advocacy, counselling, and activation programme
Number of subjects: 222
Study 15920714 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 222
Study 11788553 — intervention group
Group type: EXPERIMENTAL
Intervention: Barrett's oesophagus patients
Number of subjects: 23
Study 11788553 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 23
Study 10422856 — intervention group
Group type: EXPERIMENTAL
Intervention: Photorefractive keratectomy (PRK)
Number of subjects: 32
Study 10422856 — intervention group
Group type: COMPARATOR
Intervention: Control (unoperated contralateral eyes)
Number of subjects: 32
Study 7583900 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular buprenorphine (0.30 mg)
Number of subjects: 30
Study 7583900 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 30
Study 1973585 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebastine 10 mg
Number of subjects: 0
Study 1973585 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebastine 30 mg
Number of subjects: 0
Study 1973585 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7367820 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopy
Number of subjects: 173
Study 7367820 — intervention group
Group type: COMPARATOR
Intervention: Barium meal
Number of subjects: 173
Study 7367820 — intervention group
Group type: EXPERIMENTAL
Intervention: Parallel use of endoscopy and barium meal
Number of subjects: 173
Study 7367820 — intervention group
Group type: COMPARATOR
Intervention: Routine use of barium meal with selective use of endoscopy
Number of subjects: 173
Study 7367820 — intervention group
Group type: COMPARATOR
Intervention: X-ray examination
Number of subjects: 173
Study 31804424 — intervention group
Group type: EXPERIMENTAL
Intervention: NTS group (n = 12) performing 3 screen‐based scenarios designed to train nontechnical skills (NTS)
Number of subjects: 24
Study 31804424 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 12) performing 3 basic scenarios of the screen‐based simulation without NTS training
Number of subjects: 24
Study 27800628 — intervention group
Group type: EXPERIMENTAL
Intervention: Male gaze (objectifying gaze)
Number of subjects: 107
Study 27800628 — intervention group
Group type: COMPARATOR
Intervention: Female gaze (non-objectifying gaze)
Number of subjects: 107
Study 26501782 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard of care plus nutritional supplementation
Number of subjects: 100
Study 26501782 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 100
Study 26501782 — intervention group
Group type: EXPERIMENTAL
Intervention: NAT2 genotype (slow vs rapid/intermediate)
Number of subjects: 100
Study 26501782 — intervention group
Group type: EXPERIMENTAL
Intervention: Time on treatment
Number of subjects: 100
Study 26501782 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 100
Study 26501782 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV status
Number of subjects: 100
Study 26501782 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation
Number of subjects: 100
Study 22818804 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hygiene instruction (OHI) only
Number of subjects: 102
Study 22818804 — intervention group
Group type: EXPERIMENTAL
Intervention: OHI and 0.2% chlorhexidine mouth rinse twice daily
Number of subjects: 102
Study 22818804 — intervention group
Group type: EXPERIMENTAL
Intervention: OHI, 0.2% chlorhexidine mouth rinse twice daily, and assisted brushing twice weekly
Number of subjects: 102
Study 20922564 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZA) 4 mg IV, every 6 months
Number of subjects: 112
Study 20922564 — intervention group
Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 112
Study 20922564 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZA)
Number of subjects: 112
Study 19389420 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerised prevention program (Climate Schools: Alcohol and Cannabis prevention course)
Number of subjects: 764
Study 19389420 — intervention group
Group type: COMPARATOR
Intervention: Usual health classes
Number of subjects: 764
Study 17530360 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha2a (6 MU/day for 4 weeks, then 3 MU/day for 44 weeks)
Number of subjects: 75
Study 17530360 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha2a plus 15 mg/kg per day of ribavirin (6 MU/day for 4 weeks, then 3 MU/day for 44 weeks)
Number of subjects: 75
Study 17530360 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha2a plus ribavirin plus 200 mg/day of amantadine (6 MU/day for 4 weeks, then 3 MU/day for 44 weeks)
Number of subjects: 75
Study 15253781 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-assisted laparoscopic surgery
Number of subjects: 0
Study 15253781 — intervention group
Group type: COMPARATOR
Intervention: Standard transperitoneal laparoscopic surgery
Number of subjects: 0
Study 15253781 — intervention group
Group type: COMPARATOR
Intervention: Standard retroperitoneal laparoscopic surgery
Number of subjects: 0
Study 12588054 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary therapy (102 subjects)
Number of subjects: 256
Study 12588054 — intervention group
Group type: COMPARATOR
Intervention: Diet alone (154 subjects)
Number of subjects: 256
Study 9648992 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum zinc concentration
Number of subjects: 31
Study 9648992 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum alkaline phosphatase activity
Number of subjects: 31
Study 9648992 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc in blood cells
Number of subjects: 31
Study 8153377 — intervention group
Group type: EXPERIMENTAL
Intervention: CHART radiotherapy
Number of subjects: 47
Study 8153377 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional fractionated treatment
Number of subjects: 47
Study 8153377 — intervention group
Group type: COMPARATOR
Intervention: Both CHART and conventional treatment
Number of subjects: 47
Study 8153377 — intervention group
Group type: EXPERIMENTAL
Intervention: Parotid glands
Number of subjects: 47
Study 8153377 — intervention group
Group type: EXPERIMENTAL
Intervention: Early changes in salivary gland function
Number of subjects: 47
Study 2537340 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg clomipramine (CMI)
Number of subjects: 0
Study 2537340 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg clomipramine (CMI)
Number of subjects: 0
Study 2537340 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 135853 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast rehabilitation for patients with mild and moderate course of the disease
Number of subjects: 305
Study 135853 — intervention group
Group type: EXPERIMENTAL
Intervention: Slower rehabilitation for patients with severe lesions
Number of subjects: 305
Study 31266858 — intervention group
Group type: EXPERIMENTAL
Intervention: RACE score ≥5, taken to an endovascular capable center (ECC) as RACE-alerts (RA)
Number of subjects: 1639
Study 31266858 — intervention group
Group type: COMPARATOR
Intervention: RACE score <5, taken to the nearest hospital as stroke-alerts (SA)
Number of subjects: 1639
Study 31266858 — intervention group
Group type: EXPERIMENTAL
Intervention: RACE score ≥5
Number of subjects: 1639
Study 31266858 — intervention group
Group type: COMPARATOR
Intervention: RACE score <5
Number of subjects: 1639
Study 31266858 — intervention group
Group type: EXPERIMENTAL
Intervention: RACE-alerts (RA) with MT
Number of subjects: 1639
Study 31266858 — intervention group
Group type: COMPARATOR
Intervention: Stroke-alerts (SA) with MT
Number of subjects: 1639
Study 31801135 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (420 IU per day)
Number of subjects: 95
Study 31801135 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 27836356 — intervention group
Group type: EXPERIMENTAL
Intervention: Senna (maximum daily dose of 38.7mg)
Number of subjects: 28
Study 27836356 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene glycol (17g)
Number of subjects: 28
Study 25357149 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined aerobic and resistance exercise training (1 hr/day, three times/week for 16 weeks)
Number of subjects: 26
Study 25357149 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 26
Study 23394705 — intervention group
Group type: EXPERIMENTAL
Intervention: Busulfan plus fludarabine (BuFlu)
Number of subjects: 108
Study 23394705 — intervention group
Group type: COMPARATOR
Intervention: Busulfan plus cyclophosphamide (BuCy)
Number of subjects: 108
Study 22112329 — intervention group
Group type: EXPERIMENTAL
Intervention: Active management using synthetic oxytocin
Number of subjects: 1802
Study 22112329 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 1802
Study 22112329 — intervention group
Group type: EXPERIMENTAL
Intervention: Both active and expectant management
Number of subjects: 1802
Study 19167188 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% cetrimide
Number of subjects: 120
Study 19167188 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Number of subjects: 120
Study 19167188 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidon‐iodine
Number of subjects: 120
Study 19167188 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution (control group)
Number of subjects: 120
Study 18402129 — intervention group
Group type: EXPERIMENTAL
Intervention: Lichtenstein herniorrhaphy
Number of subjects: 100
Study 18402129 — intervention group
Group type: COMPARATOR
Intervention: Shouldice herniorrhaphy
Number of subjects: 100
Study 18402129 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Lichtenstein and Shouldice)
Number of subjects: 100
Study 18402129 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve graft contact
Number of subjects: 100
Study 14988614 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tirofiban infusion
Number of subjects: 119
Study 14988614 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 119
Study 11863317 — intervention group
Group type: EXPERIMENTAL
Intervention: Hirudin-containing cream (Hirudex cream; Hirudo medicinalis extract 280 UI/100 g) applied 3-4 times daily for 5 days
Number of subjects: 60
Study 11863317 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 9689372 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine with epinephrine
Number of subjects: 30
Study 9689372 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine and morphine with epinephrine
Number of subjects: 30
Study 9689372 — intervention group
Group type: COMPARATOR
Intervention: Placebo with epinephrine
Number of subjects: 30
Study 7639651 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0% dorzolamide three times a day
Number of subjects: 523
Study 7639651 — intervention group
Group type: COMPARATOR
Intervention: 0.5% timolol twice daily
Number of subjects: 523
Study 7639651 — intervention group
Group type: COMPARATOR
Intervention: 0.5% betaxolol twice daily
Number of subjects: 523
Study 2541335 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir (800 to 3200 mg per day, starting 6 hours before transplantation for 12 weeks)
Number of subjects: 118
Study 2541335 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 2541335 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 118
Study 2541335 — intervention group
Group type: COMPARATOR
Intervention: Acyclovir and Placebo
Number of subjects: 118
Study 12113 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromazepam (0.1 mg/kg b.w. i.v.)
Number of subjects: 4
Study 12113 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 31806692 — intervention group
Group type: EXPERIMENTAL
Intervention: Local Anesthesia (LA)
Number of subjects: 1376
Study 31806692 — intervention group
Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 1376
Study 31806692 — intervention group
Group type: COMPARATOR
Intervention: Conscious Sedation (CS)
Number of subjects: 1376
Study 30362878 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity locomotor training (LT) (70-85% HRmax)
Number of subjects: 0
Study 30362878 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity locomotor training (LT) (50-65% HRmax)
Number of subjects: 0
Study 28433774 — intervention group
Group type: EXPERIMENTAL
Intervention: Unhealthy snack condition
Number of subjects: 232
Study 28433774 — intervention group
Group type: COMPARATOR
Intervention: Fruit and vegetable condition
Number of subjects: 232
Study 24908097 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (n = 33)
Number of subjects: 66
Study 24908097 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 33)
Number of subjects: 66
Study 23171498 — intervention group
Group type: EXPERIMENTAL
Intervention: Manic episodes
Number of subjects: 34653
Study 23171498 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar disorder (I or II)
Number of subjects: 34653
Study 23171498 — intervention group
Group type: EXPERIMENTAL
Intervention: Thought disorder factor
Number of subjects: 34653
Study 23171498 — intervention group
Group type: EXPERIMENTAL
Intervention: Disorders characterized by detachment and psychoticism
Number of subjects: 34653
Study 23171498 — intervention group
Group type: EXPERIMENTAL
Intervention: Manic episodes and bipolar disorder
Number of subjects: 34653
Study 20825887 — intervention group
Group type: EXPERIMENTAL
Intervention: Airway Scope (AWS) with chest compressions
Number of subjects: 22
Study 20825887 — intervention group
Group type: COMPARATOR
Intervention: Macintosh with chest compressions
Number of subjects: 22
Study 20825887 — intervention group
Group type: COMPARATOR
Intervention: GlideScope (GVL) with chest compressions
Number of subjects: 22
Study 20825887 — intervention group
Group type: COMPARATOR
Intervention: Airway Scope (AWS) without chest compressions
Number of subjects: 22
Study 19845979 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal psychological intervention (MPI)
Number of subjects: 0
Study 19845979 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 16882344 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin AUC 5 plus pegylated liposomal doxorubicin 30 mg/m2, every 3 weeks
Number of subjects: 50
Study 14990150 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxygen compound sodium chloride solution (HCSCS)
Number of subjects: 2
Study 14990150 — intervention group
Group type: COMPARATOR
Intervention: Control sodium chloride solution (CSCS)
Number of subjects: 2
Study 15001936 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine (group 1)
Number of subjects: 285
Study 15001936 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine (group 2)
Number of subjects: 285
Study 15001936 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis B vaccine (group 3)
Number of subjects: 285
Study 10700492 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab (54 patients)
Number of subjects: 74
Study 10700492 — intervention group
Group type: COMPARATOR
Intervention: Placebo (20 patients)
Number of subjects: 74
Study 9113846 — intervention group
Group type: EXPERIMENTAL
Intervention: $5.00 suggested donation for helmets
Number of subjects: 506
Study 9113846 — intervention group
Group type: COMPARATOR
Intervention: Free helmet distribution
Number of subjects: 506
Study 8226141 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast neutron radiation therapy (20.4 Gy in 12 fractions)
Number of subjects: 200
Study 8226141 — intervention group
Group type: COMPARATOR
Intervention: Conventional photon radiotherapy (66 Gy in 33 fractions)
Number of subjects: 200
Study 8226141 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast neutron radiation therapy
Number of subjects: 200
Study 3768575 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo (inhaled aerosol described as a powerful new drug)
Number of subjects: 12
Study 3768575 — intervention group
Group type: COMPARATOR
Intervention: Bronchoconstrictive suggestion (inhaled nebulized water described as likely to cause chest tightness and wheezing)
Number of subjects: 12
Study 3768575 — intervention group
Group type: COMPARATOR
Intervention: Control (distilled nebulized water inhaled without suggestion)
Number of subjects: 12
Study 2738335 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet application during carpal tunnel release
Number of subjects: 60
Study 2738335 — intervention group
Group type: COMPARATOR
Intervention: No tourniquet application during carpal tunnel release
Number of subjects: 60
Study 30838646 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentration-based HIPEC
Number of subjects: 31
Study 30838646 — intervention group
Group type: COMPARATOR
Intervention: BSA-based HIPEC
Number of subjects: 31
Study 28350929 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 + Calcium (2000 IU/d of vitamin D3 and 1500 mg/d of calcium)
Number of subjects: 2303
Study 28350929 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2303
Study 28350929 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 + Calcium
Number of subjects: 2303
Study 25470475 — intervention group
Group type: EXPERIMENTAL
Intervention: ReliefBand (P6 acustimulation)
Number of subjects: 62
Study 25470475 — intervention group
Group type: COMPARATOR
Intervention: Sham ReliefBand
Number of subjects: 62
Study 23303057 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (HCT) 25 mg/day over 4 days
Number of subjects: 0
Study 23303057 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (HCT) 100 mg single dose
Number of subjects: 0
Study 23303057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22013791 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture combined with sevoflurane anesthesia (Group B)
Number of subjects: 80
Study 22013791 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane anesthesia (Group A)
Number of subjects: 80
Study 19242864 — intervention group
Group type: EXPERIMENTAL
Intervention: Leaflet on ecstasy use
Number of subjects: 0
Study 19242864 — intervention group
Group type: EXPERIMENTAL
Intervention: GHB materials (leaflet and infocard)
Number of subjects: 0
Study 19242864 — intervention group
Group type: EXPERIMENTAL
Intervention: Infocard about GHB
Number of subjects: 0
Study 19242864 — intervention group
Group type: EXPERIMENTAL
Intervention: Leaflet about GHB
Number of subjects: 0
Study 19242864 — intervention group
Group type: COMPARATOR
Intervention: Leaflet vs. infocard about ecstasy
Number of subjects: 0
Study 17541316 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week home‐based walking intervention (n=13)
Number of subjects: 23
Study 17541316 — intervention group
Group type: COMPARATOR
Intervention: Education-only program (control, n=10)
Number of subjects: 23
Study 15138958 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooking stove used inside a tent for 120 minutes
Number of subjects: 7
Study 11806595 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow music
Number of subjects: 48
Study 11806595 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast music
Number of subjects: 48
Study 11806595 — intervention group
Group type: EXPERIMENTAL
Intervention: Music personally selected by subjects
Number of subjects: 48
Study 11806595 — intervention group
Group type: COMPARATOR
Intervention: No music (control)
Number of subjects: 48
Study 9493587 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 anti-Xa IU x kg(-1) b.i.d. of the 10,250 IU preparation (treatment A)
Number of subjects: 12
Study 9493587 — intervention group
Group type: EXPERIMENTAL
Intervention: 180 anti-Xa IU x kg(-1) o.d. of the 20,500 IU preparation (treatment B)
Number of subjects: 12